Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR, where she has reported on accelerated drug approvals whose confirmatory trials were overdue, Operation Warp Speed contract accountability, and the ripple effects of obesity drug shortages.
Before coming to NPR, she was a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress.
Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award, and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
She can be reached via encrypted message at sydneylupkin.36 on Signal.
-
After their daughter was diagnosed with a rare inherited disease in 2013, the O'Neill family raised money to find a treatment. The Food and Drug Administration recently approved a gene therapy.
-
Dr. Heidi Overton has been nominated to be the new FDA commissioner. The Senate HELP committee pressed her on vaccines, mifepristone, food safety and whether she can tell the president he's wrong.
-
Health Secretary Robert F. Kennedy Jr.'s latest financial disclosure reveals he accepted free flights to Fiji and Greece and lucrative book advances.
-
The Trump admin's drug price deals came with a promise to offer lower prices in Medicaid. But the goalposts keep moving. Instead of all drugs, it's just one or two. And the deadlines for states to voluntarily sign on has been pushed back twice. So what's the status?